Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biofilm disrupting composition

a technology of biofilm and composition, applied in the direction of drug composition, antibacterial agent, peptide/protein ingredient, etc., can solve the problems of increasing the likelihood of significant morbidity or even death, and traditional antimicrobial therapies have been ineffective in the treatment of bacterial infections

Inactive Publication Date: 2020-01-16
WHITELEY +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a combination of a thiol based antioxidant, an enzyme, and an antibiotic that works synergistically to fight against biofilms formed by non-Pseudomonad organisms. The combination can be administered to patients to help disrupt the biofilm and treat infections.

Problems solved by technology

Traditional antimicrobial therapies have been ineffective in the treatment of bacterial infections when the bacteria are located within a biofilm which is within, adherent to, or above tissue or located within a void such as the lungs or bladder, or in nasal passages or on the surface of a wound or burn.
The additional risk of a multi-drug-resistant-organism increases the likelihood of significant morbidity or even death.
In vitro studies have shown that pyocyanin has multiple deleterious effects on mammalian cells, such as inhibition of cell respiration, ciliary function, epidermal cell growth and prostacyclin release, disruption of calcium homeostasis, and inactivation of catalase.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biofilm disrupting composition
  • Biofilm disrupting composition
  • Biofilm disrupting composition

Examples

Experimental program
Comparison scheme
Effect test

example 1

tal Protocol

[0081]Bacterial isolates were grown in Tryptone Soya Broth (TSB) medium for 24 hours at 37° C., in a shaking incubator set at 150 rpm. After this time the organisms were harvested by centrifugation (5000×g, 5 min at 10° C.). After centrifugation, the supernatant liquid was removed and the bacterial pellet was suspended in 1×Phosphate Buffered Saline (PBS). To initiate biofilm growth, the bacterial suspension from PBS was immediately re-suspended in TSB and 250 μL of bacterial cell suspension (OD600=0.5±0.05) were added into the wells of 96-well plates (Corning Corp. USA) and incubated at 37° C. for 48 h at 150 r.p.m.

[0082]After 48 h, biofilm were washed once with 1×PBS followed by treatment (for 24 h, 37° C., 150 rpm under different conditions: either with Ciprofloxacin or Amikacin, DNase I (40 U solution, Sigma Aldrich) or GSH (different concentration 10, 15 and 30 milliMolar solutions in PBS) individually or combination: DNase I+ciprofloxacin or Amikacin, GSH+DNase I, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
mean particle sizeaaaaaaaaaa
mean particle sizeaaaaaaaaaa
mean particle sizeaaaaaaaaaa
Login to View More

Abstract

A biofilm disrupting composition for use in treating biofilm-mediated infections due to non-Pseudomonas micro-organisms in the Cystic Fibrosis patient. One embodiment of the composition of the invention comprises at least one biologically acceptable thiol based antioxidant and at least one antibiotic. Another embodiment of the composition of the invention comprises at least one biologically acceptable thiol based antioxidant, at least one enzyme and at least one antibiotic. The invention is also directed to the process of preparing the composition of the invention, the use of the composition for the manufacture of a medicament for disrupting biofilms formed by non-Pseudomonad micro-organisms, and a method of disrupting biofilm formed by non-Pseudomonad micro-organisms in a patient, comprising administering to the patient the composition of the invention.

Description

FIELD OF THE INVENTION[0001]The invention relates to a biofilm disrupting composition for use in treating biofilm-mediated infections due to non-Pseudomonas micro-organisms in the Cystic Fibrosis patient.BACKGROUND OF INVENTION[0002]A biofilm is any group of microorganisms in which cells stick to each other and often these cells adhere to a surface. These adherent cells are frequently embedded within a self-produced matrix of extracellular polymeric substance (EPS). The biofilm EPS is typically comprised of a polymeric conglomeration generally composed of extracellular DNA (eDNA), proteins, and polysaccharides. Biofilms may form on living or non-living surfaces and can be prevalent in natural, industrial and hospital settings. The sessile microbial cells growing in a biofilm are physiologically distinct from planktonic cells of the same organism, which, by contrast, are single-cells that may float or swim in a liquid medium.[0003]Microbes form a biofilm in response to many factors, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/06A61K31/496A61K31/7036A61K38/46A61P31/04
CPCA61K38/465A61P31/04A61K31/7036A61K31/496C12Y301/21001A61K38/063A61K31/14A61P31/00A61P27/02A61K45/06A61K33/18A61K33/30A61K9/0014A61K9/06A61K9/08A61K47/38A61K2300/00
Inventor KUMAR, THEERTHANKAR DAS ASHISHMANOS, JIMWHITELEY, GREGORY STUARTGLASBEY, TREVOR OWEN
Owner WHITELEY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com